Autres langues X4 Pharmaceuticals, Inc.

Actions

XFOR

US98420X1037

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 17/05/2024			Varia. 5j.	Varia. 1 janv.
0,9284 ^USD	-3,26 %		-11,58 %	+10,72 %

09/05	Mise à jour sectorielle : Les actions du secteur de la santé en hausse en fin d'après-midi	MT
09/05	X4 Pharmaceuticals reçoit 125 millions de dollars de capitaux supplémentaires ; les actions augmentent	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

X4 Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference	13/05
Sector Update: Health Care Stocks Higher Late Afternoon	09/05
X4 Pharmaceuticals Receives $125 Million Additional Capital; Shares Rise	09/05
X4 Pharmaceuticals, Inc. Draws an Additional Tranche of $20 Million Under Its Existing Loan Facility with Hercules Capital, Inc	09/05
X4 Pharmaceuticals Announces $125 Million Capital Infusion from $105 Million Sale of Priority Review Voucher and $20 Million Drawdown from Existing Loan Facility	09/05
X4 Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	07/05
X4 Pharmaceuticals: Q1 Earnings Snapshot	07/05
X4 Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates	07/05
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	01/05
X4 Pharmaceuticals to Report First-Quarter 2024 Financial Results and Host a Conference Call and Webcast on May 7, 2024	30/04
Pantherx® Rare Partner with X4 Pharmaceuticals Inc. for the Distribution of Xolremdi? (Mavorixafor), the First FDApproved Therapy Indicated for Use in Patients with Whim Syndrome	29/04
X4 Pharmaceuticals' Xolremdi Approved by FDA For WHIM Syndrome	29/04
X4 Pharmaceuticals Gets FDA Approval for Xolremdi Capsules	29/04
X4 Pharmaceuticals Announces FDA Approval of XOLREMDI™ (mavorixafor) Capsules, First Drug Indicated in Patients with WHIM Syndrome	29/04
X4 Pharmaceuticals, Inc. Announces FDA Approval of XOLREMDI (mavorixafor) Capsules, First Drug Indicated in Patients with Whim Syndrome	29/04
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)	03/04
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	02/04
X4 Pharmaceuticals : Regulation FD Disclosure - Form 8-K	01/04
X4 Pharmaceuticals to Participate in Upcoming April Investor Conferences	01/04
X4 Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	21/03

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues X4 Pharmaceuticals, Inc.

Actions

XFOR

US98420X1037

Autres langues

Filtres